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INTRODUCTION
Aplastic anemia is a rare disorder most with a bi-modal age
presentation, arising both early and late in life [1]. Although aplastic
anemia is relatively rare in childhood, its medical impact remains
high with life-threatening consequences entailing complex medical
therapies and potential long-term complications. Published evi-
dence to guide clinical management of aplastic anemia in children
remains scarce. The rapidly growing armamentarium of tests for
genetic factors contributing to aplastic anemia raises new questions
with regard to diagnostic workup and treatment decisions.
METHODS
Because of the paucity of data to guide medical management of
aplastic anemia in children, 18 pediatric hematology centers with an
interest in aplastic anemia have initiated the North American
Pediatric Aplastic Anemia Consortium (NAPAAC). The NAPAAC
collaborative working group conducted a survey of its members to
determine current practices for the diagnostic workup, treatment,
and medical management of pediatric aplastic anemia in North
America.
RESULTS
Diagnosis Definition, Severity Classification and Initial
Diagnostic Evaluations
We surveyed 18 children’s hospitals in the United States and
Canada regarding laboratory-based diagnostic and treatment
practices for pediatric aplastic anemia. All institutions completed
the survey in its entirety. Sixty percent of the respondents used
criteria for severe aplastic anemia (SAA) modified after those
described by Camitta and colleagues [2] with an absolute neutrophil
count (ANC) <500/ml, platelets <20,000/ml, and absolute
Background. Randomized clinical trials in pediatric aplastic
anemia (AA) are rare and data to guide standards of care are scarce.
Procedure. Eighteen pediatric institutions formed the North Ameri-
can Pediatric Aplastic Anemia Consortium to foster collaborative
studies in AA. The initial goal of NAPAAC was to survey the
diagnostic studies and therapies utilized in AA. Results. Our survey
indicates considerable variability among institutions in the diagnosis
and treatment of AA. There were areas of general consensus,
including the need for a bone marrow evaluation, cytogenetic and
specific fluorescent in situ hybridization assays to establish diagnosis
and exclude genetic etiologies with many institutions requiring
results prior to initiation of immunosuppressive therapy (IST); uniform
referral for hematopoietic stem cell transplantation as first line
therapy if an HLA-identical sibling is identified; the use of first-line
IST containing horse anti-thymocyte globulin and cyclosporine A
(CSA) if an HLA-identical sibling donor is not identified; supportive
care measures; and slow taper of CSA after response. Areas of
controversy included the need for telomere length results prior to IST,
the time after IST initiation defining a treatment failure; use of
hematopoietic growth factors; the preferred rescue therapy after
failure of IST; the use of specific hemoglobin and platelet levels as
triggers for transfusion support; the use of prophylactic antibiotics;
and follow-up monitoring after completion of treatment. Conclu-
sions. These initial survey results reflect heterogeneity in diagnosis
and care amongst pediatric centers and emphasize the need to
develop evidence-based diagnosis and treatment approaches in this
rare disease. Pediatr Blood Cancer 2014;61:869–874.
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reticulocytes<20,000/ml and bone marrow (BM) cellularity<25%
for age. Forty percent of respondents noted that two out of three
blood count criteria along with marrow hypocellularity were
sufficient. The absolute reticulocyte count (ARC) required for
diagnosis varied among some institutions between <40,000 and
<60,000/ml. An ANC <200/ml uniformly defined very severe
aplastic anemia (vSAA) from SAA. Three respondents used the
ARC to distinguish SAA (ARC <60,000/ml) from vSAA (ARC
<40,000/ml). Taken together, these institutions see approximately
75–80 new patients ages 1–18/year with acquired aplastic anemia.
Moderate AA (mAA) was defined in 60% of the centers as Hb
<10 g/dl, ANC <1,500/ml, platelets <50,000/ml, ARC <40,000/
ml, and BM cellularity 25–50%. Some institutions used a platelet
count<60,000/ml and/or BM cellularity<50% for the diagnosis of
mAA. Several institutions utilized broader criteria comprising any
abnormal decreased blood count with a hypocellular BM and not
fulfilling the criteria for SAA or vSAA.
All 18 centers uniformly included BM cytogenetics in the
diagnostic work-up at presentation (Table I). Sixty percent of
institutions included fluorescent in situ hybridization (FISH) studies
for monosomy 7, 5q, and 8 chromosome gain, while 22%
included chromosomes 22q, 20, and 9 FISH probes. Over 90% of
those who do cytogenetics or FISH would await these results prior
to IST or hematopoietic stem cell transplantation (HSCT). Two-
thirds of respondents analyzed BM for T, B, and CD34þ cells by
flow cytometry. Eighty-nine percent evaluated paroxysmal noctur-
nal hemoglobinuria (PNH) by flow cytometry. Almost all (94%)
respondents performed HLA typing of patient and siblings, while
78% of institutions routinely included parental typing at the time
of diagnosis.
Diagnostic tests to exclude viral causes of AA included EBV,
CMV, and hepatitis A, B, and C in 80% of centers. The status of
HIV, HSV, VZV, or HHV6was also evaluated in 33–44% of centers,
while parvovirus B19 was assayed in <17% of institutions. Eleven
percent of respondents did not do viral testing at initial evaluation.
Of the centers that do viral testing, up to 70% would await results
prior to therapy. Approximately half of respondents measured
vitamin B12 and folate levels, while a similar proportion (44%)
assessed immune function by measuring lymphocyte numbers,
T and B cell subsets and immunoglobulin levels.
Evaluations for Constitutional Etiologies
Most respondents excluded inherited bone marrow failure
syndromes which would lead to alternative therapies (Table I).
Eighty-nine percent of institutions performed testing for Fanconi
anemia (FA). Fifty-eight percent of institutions which perform these
tests delay IST or HSCT until results are available. Sixty-seven
percent performed telomere length analysis for dyskeratosis
congenita (DC). If telomere length testing was suspicious for
DC, follow-up genetic testing was typically sent. Additionally, a
diagnosis or suspicion of DC or FA led to testing of family
members. Some centers utilized DC testing upon re-evaluation of
patients whose disease is refractory to ISTand for research purposes
(see below). As an initial molecular diagnostic workup, 71%
ordered sequencing of the Shwachman–Bodian–Diamond syn-
drome gene (SBDS), while 40% of respondents evaluated genes
causing DC (DKC1, TERT, TERC, TINF2, and NOP10/NHP2)
and the and amegakaryocytic thrombocytopenia-associated gene
(c-MPL, the thrombopoietin receptor). Biochemical, radiographic,
and ultrasound investigations for internal physical anomalies for
SBDS, FA, and Diamond–Blackfan–Aaemia (DBA) were infre-
quently (0–22%) performed as a routine diagnostic workup for
aplastic anemia.
Initial Treatment of SAA
There was consensus to proceed with a matched sibling donor
(MSD) HSCT if a donor was identified at the time of initial
diagnosis of SAA or vSAA. Thirty-eight percent of respondents,
however, would consider IST as primary treatment despite the
availability of a MSD under certain circumstances. These circum-
stances include family concerns regarding fertility (39%), family
preference for IST (28%), an anticipated delay of greater than
6–8 weeks until HSCT (33%), and significant psycho-social
barriers to BMT (28%). Seventy-five percent of respondents did not
feel comfortable using autologous cord blood as a source for HSCT.
Immunosuppression Therapy
All but one of the institutions used an IST regimen consisting of
anti-thymocyte globulin (ATG) and cyclosporine A (CSA). The
remaining institution utilized high-dose cyclophosphamide alone
for immunosuppression. The majority of institutions (67%)
consider initiating IST within 21 days of diagnosis to be very
important for successful outcome. All institutions would utilize
horse ATG rather than rabbit ATG for initial IST. Most commonly
the patients receive a test dose of ATG followed by 40mg/kg/dose
daily for 4 days, but 25% of institutions treat patients for 5 days. The
ATG is given over 4–10 hours with most centers using an 6–8-hour
infusion duration. Half of the centers escalate the dose of ATG
TABLE I. Diagnostic Workup
Test % Centers
Bone Marrow Asp/Bx 100%
Cytogenetics 100%
HLA typing of siblings 94%
Chromosome breakage analysis-MMCa/DEBb 89%
PNHc Screen by Flow 89%
EBVd, CMVe 83%
Hepatitis screen 78%
SBDSf gene sequencing 71%
Telomere length 67%
FISH (chr 5, 7, 8) 61%
BM Flow for T,B, CD34 67%
Immunological work-up 55%
Vit B12, Folate 50%
DCg Genetic Testing 43%
HSVh, VSVi, HHV6j 33%
Ferritin 28%
Pancreas U/S 22%
Kidney U/S 16%
Skeletal survey/Hand film 0%
aMMC is defined as Mitomycin C; bDEB is defined as Diepoxybutane;
cPNH is defined as Paroxysmal Nocturnal Hemoglobinuria; dEBV is
defined as Epstein–Barr Virus; eCMV is defined as Cytomegalovirus;
fSBDS is defined as Shwachman–Bodian–Diamond Syndrome; gDC is
defined as Dyskeratosis Congenita; hHSV is defined as Herpes Simplex
Virus; iVSV is defined as Vesicular Stomatitis Virus; jHHV6 is defined
as Human Herpesvirus 6.
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slowly on the first day of treatment. Premedication with
diphenhydramine and acetaminophen is common. Methylprednis-
olone is added by the majority of centers to minimize the risk for
serum sickness as well as to reduce infusion reactions. Most
protocols include intravenous methylprednisolone 2mg/kg/day
with ATG, given every 6 or 12 hours, which is changed to oral
prednisone to complete a 4–14-day course followed by a tapering
schedule. The institutions vary with respect to the location where
IST is carried out, utilizing either positive pressure single
occupancy rooms (50%), standard single occupancy rooms
(44%), an open general hematology ward with two or more
patients (28%), or a bone marrow transplant ward (17%).
ATG is uniformly given with CSA. Most commonly used CSA
formulations were Neoral1 or Gengraf1, both of which are
modified formulations. The starting dose of CSA ranged from 2.5
to 7.5mg/kg/dose given every 12 hours to maintain CSA trough
levels of 150–250mg/L, measured by monoclonal antibody (33%)
assay or HPLC (28%) in local laboratories. Some institutions
utilized a range of 100–200mg/L while others utilized 200–
400mg/L.
Supportive Care
Practices for blood product support are summarized in Table I.
Leukoreduced “CMV-safe products” were universally utilized
while 59% of institutions specifically requested CMV-negative
donors if the patient’s initial CMV serology is negative. Irradiated
blood products are specifically requested by 80% of those surveyed
(44% of institutions irradiate all blood products).
There is also variability in packed red blood cell transfusion
practices as outlined in Table II. Based on concerns with alloim-
munization and iron overload, there was a uniform approach to
utilize as few transfusions as possible to keep the patient relatively
asymptomatic. Nearly all institutions (87%), however, agree that
there is a lower limit of acceptable hemoglobin for which most
patients should be transfused regardless of symptoms, although this
level varied significantly from 5.0 to 8.0G/dl. Some programs
utilize patient-specific parameters including clinical symptoms,
degree of reticulocytopenia, proximity of a weekend, distance from
the hospital, expected follow up, and planned activities to develop a
tailored approach to transfusion therapy.
A significant number (71%) of institutions prophylactically
maintain platelet counts at least above 10,000/ml throughout
treatment and the majority of these (92%) attempt to maintain the
platelet count at least above 20,000/ml during administration of
ATG (Table II). Granulocyte transfusions are used very rarely in the
treatment of pediatric patients with aplastic anemia. In these
instances they are employed only in the setting of refractory or life-
threatening infection in patients with severe neutropenia and no
anticipated immediate neutrophil recovery.
Thirty-seven percent of responding institutions report using
granulocyte colony stimulating factor (G-CSF) in patients from the
beginning of therapy (Table III). Sixty-nine percent of respondents
said they would use G-CSF in the setting of an active infection and
no ANC recovery. GM-CSF is occasionally used in combination
with G-CSF if there is an active infection and the patient’s ANC has
not responded to G-CSF.
Prophylactic antimicrobial practices are summarized in
Table IV. Most institutions provide Pneumocystis jiroveci prophy-
laxis throughout the treatment course. Seventy-two percent of
institutions use antifungal medications. However, 22% of the
institutions surveyed do not use any prophylactic antibacterial or
antifungal agents regardless of blood counts. Those institutions that
provide antibiotic prophylaxis generally discontinue the medica-
tions once the ANC has met a specific threshold, ranging from 500
to 1,000/ml. The most commonly used broad-spectrum antibiotics
reported are ciprofloxacin and levofloxacin; the most commonly
reported anti-fungal agents are fluconazole and voriconazole.
Acyclovir prophylaxis is used by some institutions.
Participants were asked to comment on neutropenic precautions
and vaccination policy. Free text comments ranged from not
providing any specific precautions, using “common sense”
regarding people who are obviously ill, avoiding construction,
and demolition sites, to specific instructions regarding cooking
foods, hand washing, bathing daily, wearing of masks, and other
instructions. Patients are uniformly instructed to seek medical
attention for any temperature elevation. Instructions regarding
TABLE II. Blood Product Utilization
Blood product preparation
Leukoreduced blood products 100%
Routine extended cross matching 20%
Radiated blood products specifically requested 81%
All blood products radiated at institution 44%
Use CMV negative product if initial serology
is negative
59%
Red cell administration
Maintain RBC above a certain level (6–8 g/dl) 50%
Transfuse RBC only when patient is symptomatic 31%
Use minimal transfusion to keep patients
asymptomatic
88%
Have lower acceptable hemoglobin level (5–8 g/dl) 88%
Think that excessive transfusion delays recovery 20%
Platelet administration
Maintain platelets above a certain level
during ATGa
82%
10,000/ml 8%
20,000/ml 64%
30,000/ml 14%
50,000/ml 14%
Prophylactically transfuse platelets in
steady state
71%
10,000/ml 91%
15,000/ml 8%
Granulocyte transfusions
Utilization
Sometimes 13%
Rarely 63%
Never 25%
aATG is defined as anti-thymocyte globulin.
TABLE III. Myeloid Growth Factor Usage
G-CSFa
Routine use throughout treatment 37.5%
Use for infection with neutropenia 68.8%
GM-CSFb
Use for infection if no response to G-CSF 23%
Use for duration of active infection 38%
aG-CSF is defined as granulocyte colony-stimulating factor. bGM-CSF
is defined as granulocyte macrophage colony-stimulating factor.
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returning to school were also quite varied from “any time they are
not in the hospital” to more detailed recommendations. Similarly,
recommendations regarding immunizations were varied from
“no set policy and no restrictions,” no live virus vaccines, to
administration after specific time periods and/or keyed to the
absolute lymphocyte count.
Follow-Up and Evaluation of Treatment Responses
The majority of survey respondents used a variety of measures
as treatment response markers justifying a continuation of IST. A
complete response (CR) to IST was defined as return to normal
blood counts. A partial response (PR) was present when the patient
was transfusion independent in the setting of continued abnormal
counts. These definitions were consistent across all institutions.
Only 22% of respondents felt that positive changes inmore than one
cell line were required to indicate a treatment response. However,
less than half of institutions (44%) used a specific ANC and/or
platelet threshold to define a minimal response. Moreover, the
specific threshold value used in these institutions varied widely,
for ANC from 200 to 1,000/ml and for platelets from 20 to 100
103/ml. All respondents considered failure to respond to IST by lack
of attainment of transfusion independence and ANC <500/ml in
6 months post-treatment initiation as treatment failure although
some institutions considered 3 months post-treatment initiation as
an early indication of IST failure.
Upon achievement of a complete response, there was consider-
able variation in evaluations performed prior to weaning CSA
(Table V). Thirty-nine percent of surveyed institutions recom-
mended a repeat BM aspirate and biopsy with cytogenetic
evaluation while 28% specifically recommended no repeat testing.
Seventeen percent of institutions performed PNH and CBC
screening only. However, for patients who achieved only a stable
partial response, a higher proportion of survey respondents (61%)
would perform BM aspirate and biopsy prior to weaning therapy,
whereas only 6% would do no further testing. One-third (33%) of
respondents would continue CSA for a period ranging from 2 to
12 months beyond the time a stable partial response is achieved in
order to determine whether further count improvement would occur
before considering weaning therapy. There was consensus among
all respondents that CSA should not be discontinued as soon as a
complete response is established; however, there was considerable
variability among respondents with regard to the duration of
full dose CSA therapy from the time of therapy initiation (range 3–
15 months), and specifically in the duration of consolidation
treatment with full dose CSA after achieving complete remission
(range 2–12 months).
Once treatment is discontinued, most respondents included
routine clinic visits (61%) and blood counts (72%) as part of
ongoing monitoring. However, the period of frequent monitoring
after therapy discontinuation ranged from 3 to 12 months for
patients with CR and from 3 to 24 months for patients with stable
PR, with blood counts every 0.5–2 months. Thirty-one percent of
institutions would perform follow-up bone marrow exam once off
therapy with CR or stable PR annually. Some institutions would
perform at least one bonemarrow examwith cytogenetics following
therapy cessation, particularly for patients with stable PR.
With regard to long-term monitoring after recovery, about 80%
of respondents reported a consistent approach at their institution,
but the specifics of the monitoring protocols varied widely. The
frequency of routine physical exams and blood counts during later
follow-up varied from every 2 months to 12 months. Sixty-six
percent would consider discharging patients with CR from their
hematology clinics at 5–10 years post-therapy cessation, whereas
only 11% would discharge a patient with stable partial response.
Notably, nearly 10% of respondents stated they would never
discharge a patient with aplastic anemia from follow-up. All
respondents agreed that a bone marrow aspirate with cytogenetics
should be performed with a change in blood counts indicative
of recurrence or worsening of marrow failure or of malignant
transformation.
Treatment of Resistant and Relapsed Disease
Lack of response to initial IST. With regard to treatment
options when there was no response to IST with the patient still
meeting criteria for SAA, 72% of respondents would refer the
patient for HSCTand/or start a search for amatched unrelated donor
(MUD). If no acceptable MUD was available for a patient who
failed IST, most centers would consider a second course of ATG/
CSA. Alternative second line therapies, other than a second course
of ATG/CSA, included eltrombopag (33%), cyclophosphamide
(28%), and alemtuzumab (28%). Some centers would consider
haploidentical HSCT in the absence of an acceptable MUD. For the
second course of ATG, 13% of respondents would use horse ATG,
27%would use horse ATG unless there had been a severe reaction to
the initial treatment, 20% would use rabbit ATG, and 40% would
use the opposite form of ATG to the one given initially.
Relapse on treatment. For patients whose counts were
declining after an initial response to IST while still on CSA, 78%
of respondents would repeat the bone marrow aspirate, biopsy, and
cytogenetics and 39% would perform additional work-up including
evaluation for inherited marrow failure (e.g., telomere length and
SBDS testing, if not previously performed) and flow cytometry for
PNH. Eighty-three percent would increase the dose of CSA to reach
therapeutic levels if a taper had been started. Twenty-two percent
TABLE V. Lab Tests Prior to Tapering Cyclosporine
Complete response
Bone marrow aspirate/biopsy/cytogenetics 39%
PNHa 17%
No further testing 28%
Other 16%
Partial response
Bone marrow aspirate/biopsy/cytogenetics 61%
No further testing 6%
Other 33%
aPNH is defined as paroxysmal nocturnal hemoglobinuria.
TABLE IV. Antimicrobial Prophylaxis
Antimicrobial agent
%
Centers Throughout
First
month
No prophylactic antibiotics 22%
Bactrim 28% 100% 0%
Aerosol pentamidine 39% 86%
Fluconazole 33.3% 66.7% 33.3%
Voriconazole 39% 86%
Other 44%
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would continue the current CSA dose (assuming that there were
adequate blood levels of CSA) unless and until criteria for SAA
developed again. No respondents indicated that they would
immediately repeat treatment with ATG before criteria for SAA
were reached. None of the surveyed institutions would utilize MUD
HSCT for first line therapy.
Relapse off treatment. Fifty-six percent of respondents
would re-start treatment as soon as there was a clear trend of
recurrent marrow failure in patients off treatment. Seventeen
percent would continue to observe until the patient met the criteria
for SAA again. Sixty-one percent advocated “rescue” treatment for
first relapse after ISTwithATG/CSA. Among thosewhowould treat
with ISTas first-line therapy for relapse, 73% would start searching
for a donor at the same time as initiation of the second IST, but two
respondents would start a search for a donor only if there were no
response to the second IST within 3 or 6 months. If no acceptable
donor were found, for a second (or higher) relapse, 61% would
consider repeating IST. A variety of other second-line therapies
would be considered with similar frequency, including cyclophos-
phamide, eltrombopag and alemtuzumab. Less frequently used
approaches in this setting included danazol and haploidentical
HSCT.
DISCUSSION
Severe aplastic anemia in children and adolescents is a rare
disease with an estimated incidence of 1–3 cases per million [3,4].
The rarity of pediatric aplastic anemia poses difficulties for
establishing guidelines for front-line treatment, salvage therapies,
and supportive care. To address this challenge, a group of pediatric
hematologists formed the North American Pediatric Aplastic
Anemia Consortium. As a first step toward the development of
diagnostic and therapeutic protocols, we surveyed 18 prominent
pediatric hematology services. We found considerable variability
in diagnostic work-up, supportive care, and the approach to
patients with disease that is refractory to treatment or with
relapsed disease.
Congruent with published algorithms for the initial treatment of
acquired SAA in the pediatric age group [5–7], all surveyed
institutions recommend HSCT if a MSD is identified. In light of
improved outcomes of MUD for acquired SAA, some have
proposed upfront therapywith a 10/10HLA-A, -B, -C, -DRB1, -DQ
high resolution MUD HSCT [8]. However, the NAPAAC centers
uniformly recommended IST, rather than MUD, if an HLA-
matched sibling donor was not identified due to the morbidity and
mortality still associated with MUD in this setting.
All surveyed institutions preferentially use horse- rather than
rabbit-derived ATG in their ATG-CSA regimens, a choice
supported by results of a randomized trial demonstrating
significantly lower response rates and survival with rabbit
ATG [9]. Although this trial did include children, it was not
powered to evaluate pediatric patients as an independent
variable. A retrospective study in children has recently been
published [10]. Therefore, whether horse ATG is superior to
rabbit ATG in the pediatric population remains to be deter-
mined [11]. The timing and duration of the CSA taper varied
widely among respondents. Whether these differences translate
into differences in relapse rates is unknown. Overall the majority
of supportive care practices were consistent with published
reviews [7,12]. However, some practice differences and devia-
tions from published literature highlighted persistent, important
management questions.
The use of upfront IST as first line therapy in the absence of
MSD and transfusion practices were the areas of most
consistency amongst surveyed institutions. More than a third
of institutions surveyed reported using G-CSF from the onset of
disease despite a multi-center, randomized study that demon-
strated no difference in overall or event-free survival [13]. Since
this study did demonstrate reduced numbers of febrile events and
in-patient hospital days, the variable practices may reflect
differences in importance placed on costs versus risks of side
effects of G-CSF. Antimicrobial prophylaxis was an interesting
areas of divergence in practice. Twenty-two percent of the
respondents use no prophylaxis. Three fourths use prophylaxis
against Pneumocystis jiroveci as recommended by a recent
review [7] although the literature is not definitive on Pneumo-
cystis sp. as a frequent complication in aplastic anemia outside
the setting of HSCT [14]. Similarly, use of antibacterial and
antifungal agents was common in spite of their controversial
efficacy in prolonged neutropenia [7,15].
For patients with disease refractory to initial IST, only aminority
recommended repeat IST treatment unless no MUD was available.
If a patient initially responded but was becoming more cytopenic
during CSA taper, the large majority of respondents return to full
dose CSA treatment. For patients who “relapsed” off treatment, the
majority of respondents would promptly initiate “rescue” treatment
with ATG/CSA, but would simultaneously pursue the availability of
a MUD transplant.
SUMMARY
Acquired aplastic anemia is a rare disorder and randomized
clinical trials in pediatric aplastic anemia are infrequent [16–18]
although some adult trials include small numbers of children.While
reported in Japanese, Korean, and European populations [19–22],
large, multi-institutional studies focused on North American
patients have not been described. Standards of care in North
America are currently institution-specific. While the results
presented from this survey of multiple pediatric institutions
demonstrate some areas of consensus in diagnostic work-up and
treatment, a great deal of variability exists. These data suggest
opportunities to standardize care and develop multi-institutional
prospective trials to compare treatment approaches and outcomes of
pediatric AA in North America with those of other regions and
collaborative groups, with the goal of advancing the field with new
therapeutic interventions.
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